MAB3878
抗-MyoD1抗体
clone 5.2F, Chemicon®, from mouse
别名:
Anti-MYF3, Anti-MYOD, Anti-MYODRIF, Anti-PUM, Anti-bHLHc1
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
5.2F, monoclonal
Application:
ICC, IHC, IP, WB
Citations:
8
biological source
mouse
Quality Level
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
5.2F, monoclonal
species reactivity
rat, mouse, chicken, human
manufacturer/tradename
Chemicon®
technique(s)
immunocytochemistry: suitable, immunohistochemistry: suitable, immunoprecipitation (IP): suitable, western blot: suitable
isotype
IgG2a
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... MYOD1(4654)
General description
约45 kDa
Immunogen
来自小鼠MyoD1的重组蛋白。
Application
抗MyoD1抗体是一种用于检测MyoD1的高质量小鼠单克隆抗体，&已在ICC、IHC、IP & WB中进行了验证。
蛋白质印迹：1 μg/mL。与~45 kD蛋白反应。
针对冷冻和福尔马林固定、石蜡包埋组织的免疫组织化学：2-4 μg/mL。
免疫细胞化学
免疫沉淀：2 μg/mg蛋白裂解物
最佳工作稀释度必须由最终用户确定。
针对冷冻和福尔马林固定、石蜡包埋组织的免疫组织化学：2-4 μg/mL。
免疫细胞化学
免疫沉淀：2 μg/mg蛋白裂解物
最佳工作稀释度必须由最终用户确定。
Biochem/physiol Actions
识别MyoD1。该表位位于小鼠MyoD1蛋白N末端的3-56位氨基酸。
Physical form
形式：纯化
Analysis Note
对照
胎儿肌肉，横纹肌肉瘤
胎儿肌肉，横纹肌肉瘤
Other Notes
浓度：关于批次特定浓度请参见检验报告。
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
相关内容
A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
Kohsaka, S; Shukla, N; Ameur, N; Ito, T; Ng, CK; Wang, L; Lim, D; Marchetti, A; Viale et al.
Nature Genetics null
L V Renna et al.
European journal of histochemistry : EJH, 58(4), 2444-2444 (2015-01-13)
Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are multisystemic disorders linked to two different genetic loci and characterized by several features including myotonia, muscle weakness and atrophy, cardiac dysfunctions, cataracts and insulin-resistance. In both forms, expanded nucleotide sequences
Francesca Megiorni et al.
Journal of hematology & oncology, 10(1), 161-161 (2017-10-08)
EPH (erythropoietin-producing hepatocellular) receptors are clinically relevant targets in several malignancies. This report describes the effects of GLPG1790, a new potent pan-EPH inhibitor, in human embryonal rhabdomyosarcoma (ERMS) cell lines. EPH-A2 and Ephrin-A1 mRNA expression was quantified by real-time PCR
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| MAB3878 | 04053252725661 |